Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug
You may also be interested in...
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
MUMBAI - After a prolonged decision-making process, India's Glenmark Pharmaceuticals is likely to halt development of potential compounds melogliptin (GRC 8200) and pain management drug GRC 6211